$TSVT
2seventy bio, Inc. Stock $tsvt

$tsvt Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000186078223000076 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$36.05M	$41.62M	$8.429M
YoY Change	167.38%	393.78%	-29.17%
Cost Of Revenue	$907.0K	$641.0K	$511.0K
YoY Change	149.18%	25.44%	-70.01%
Gross Profit	$35.14M	$40.98M	$7.918M
YoY Change	167.88%	417.55%	-22.35%
Gross Profit Margin	97.48%	98.46%	93.94%
Selling, General & Admin	$19.49M	$20.72M	$23.86M
YoY Change	12.8%	-13.16%	-3.11%
% of Gross Profit	55.46%	50.56%	301.35%
Research & Development	$59.98M	$68.25M	$69.25M
YoY Change	-12.36%	-1.44%	-10.73%
% of Gross Profit	170.68%	166.53%	874.53%
Depreciation & Amortization	$2.238M	$2.255M	$3.530M
YoY Change	-32.2%	-36.12%	-3.97%
% of Gross Profit	6.37%	5.5%	44.58%
Operating Expenses	$79.47M	$88.97M	$93.11M
YoY Change	-7.38%	-4.45%	-8.9%
Operating Profit	-$47.99M	-$51.71M	-$90.59M
YoY Change	-33.97%	-42.91%	-1.93%
Interest Expense	$3.090M	$2.049M	$115.0K
YoY Change	1350.7%	1681.74%
% of Operating Profit
Other Income/Expense, Net	$2.812M	$2.643M	$4.762M
YoY Change	-536.65%	-44.5%	-7.96%
Pretax Income	-$42.09M	-$47.02M	-$85.71M
YoY Change	-45.62%	-45.14%	-1.7%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$42.09M	-$47.00M	-$85.70M
YoY Change	-45.64%	-45.16%	-1.72%
Net Earnings / Revenue	-116.76%	-112.92%	-1016.73%
Basic Earnings Per Share	-$0.83	-$1.08	-$3.20
Diluted Earnings Per Share	-$0.83	-$1.08	-$3.20
COMMON SHARES
Basic Shares Outstanding	50.20M shares	50.19M shares	26.75M shares
Diluted Shares Outstanding	50.97M shares	43.47M shares	26.75M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$282.8M	$339.9M	$377.9M
YoY Change	-20.98%	-10.04%
Cash & Equivalents	$95.99M	$193.6M	$270.9M
Short-Term Investments	$186.8M	$146.3M	$107.0M
Other Short-Term Assets	$6.729M	$8.635M	$18.00M
YoY Change	-51.25%	-52.03%
Inventory
Prepaid Expenses	$6.729M	$8.635M	$18.00M
Receivables	$44.10M	$41.25M	$16.93M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$333.7M	$389.8M	$412.8M
YoY Change	-13.08%	-5.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$61.02M	$59.15M	$35.04M
YoY Change	-79.94%	68.83%
Goodwill	$12.06M	$12.06M	$12.06M
YoY Change		0.0%
Intangibles	$6.948M	$7.125M	$8.774M
YoY Change		-18.79%
Long-Term Investments	$23.71M	$1.432M	$74.68M
YoY Change	-41.66%	-98.08%
Other Assets	$37.60M	$37.59M	$37.75M
YoY Change	-3.65%	-0.41%
Total Long-Term Assets	$372.0M	$352.6M	$439.1M
YoY Change	-7.8%	-19.7%
TOTAL ASSETS
Total Short-Term Assets	$333.7M	$389.8M	$412.8M
Total Long-Term Assets	$372.0M	$352.6M	$439.1M
Total Assets	$705.7M	$742.4M	$851.9M
YoY Change	-10.37%	-12.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.274M	$13.40M	$13.65M
YoY Change	-6.15%	-1.82%
Accrued Expenses	$47.98M	$55.05M	$68.54M
YoY Change	-39.89%	-19.68%
Deferred Revenue	$12.64M	$8.480M	$5.000M
YoY Change		69.6%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$66.90M	$76.93M	$106.3M
YoY Change	-32.44%	-27.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.404M	$2.401M	$2.431M
YoY Change	-99.22%	-1.23%
Total Long-Term Liabilities	$2.404M	$2.401M	$2.431M
YoY Change	-99.22%	-1.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$66.90M	$76.93M	$106.3M
Total Long-Term Liabilities	$2.404M	$2.401M	$2.431M
Total Liabilities	$338.2M	$341.1M	$404.5M
YoY Change	-17.19%	-15.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$382.8M	-$340.7M	-$125.2M
YoY Change		172.09%
Common Stock	$5.000K	$5.000K	$4.000K
YoY Change		25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$367.5M	$401.3M	$447.4M
YoY Change
Total Liabilities & Shareholders Equity	$705.7M	$742.4M	$851.9M
YoY Change	-10.37%	-12.85%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$42.09M	-$47.00M	-$85.70M
YoY Change	-45.64%	-45.16%	-1.72%
Depreciation, Depletion And Amortization	$2.238M	$2.255M	$3.530M
YoY Change	-32.2%	-36.12%	-3.97%
Cash From Operating Activities	-$32.66M	-$49.10M	-$74.10M
YoY Change	-30.0%	-33.74%	14.44%
INVESTING ACTIVITIES
Capital Expenditures	$3.971M	$6.079M	$3.585M
YoY Change	-248.56%	69.57%	-43.55%
Acquisitions
YoY Change
Other Investing Activities	-$60.91M	$50.88M	$48.33M
YoY Change	-216.15%	5.26%
Cash From Investing Activities	-$64.88M	$44.80M	$44.75M
YoY Change	-230.36%	0.11%	-804.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	128.0K	$127.1M	$170.1M
YoY Change	-102.99%	-25.29%	139.24%
NET CHANGE
Cash From Operating Activities	-32.66M	-$49.10M	-$74.10M
Cash From Investing Activities	-64.88M	$44.80M	$44.75M
Cash From Financing Activities	128.0K	$127.1M	$170.1M
Net Change In Cash	-97.42M	$122.8M	$140.8M
YoY Change	8240.41%	-12.78%
FREE CASH FLOW
Cash From Operating Activities	-$32.66M	-$49.10M	-$74.10M
Capital Expenditures	$3.971M	$6.079M	$3.585M
Free Cash Flow	-$36.63M	-$55.18M	-$77.69M
YoY Change	-16.72%	-28.97%	9.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001860782
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q3	tsvt	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	0.3333
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40791
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	2seventy bio, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3658454
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Binney Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	City Area Code CityAreaCode	339
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	499-9300
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	TSVT
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50199268	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193629000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71032000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	146301000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Current DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent	195238000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8635000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13652000	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	41252000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	20960000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	389817000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	300882000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59153000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55735000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	1432000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Noncurrent DebtSecuritiesAvailableForSaleExcludingAccruedInterestNoncurrent	1414000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7125000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7302000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	12056000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12056000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235264000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	240885000	usd
CY2023Q1	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	37590000	usd
CY2022Q4	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	38391000	usd
CY2023Q1	us-gaap	Assets Assets	742437000	usd
CY2022Q4	us-gaap	Assets Assets	656665000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	13399000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7208000	usd
CY2023Q1	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	43568000	usd
CY2022Q4	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	54678000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11482000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11164000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8480000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3000000	usd
CY2023Q1	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	0	usd
CY2022Q4	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	3744000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	76929000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79794000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6311000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5000000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	255472000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259008000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2401000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2397000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	341113000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	346199000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50190000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50190000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37928000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37928000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	743937000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	606986000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1950000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2877000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-340668000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293647000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	401324000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	310466000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	742437000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	656665000	usd
CY2023Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	29372000	usd
CY2022Q1	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3487000	usd
CY2023Q1	us-gaap	Revenues Revenues	41621000	usd
CY2022Q1	us-gaap	Revenues Revenues	8429000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	68246000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65879000	usd
CY2023Q1	tsvt	Manufacturing Costs Under Commercial Arrangements ManufacturingCostsUnderCommercialArrangements	3654000	usd
CY2022Q1	tsvt	Manufacturing Costs Under Commercial Arrangements ManufacturingCostsUnderCommercialArrangements	3366000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20720000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	23861000	usd
CY2023Q1	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	usd
CY2022Q1	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-5352000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	641000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	511000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	73000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	48000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	93334000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	99017000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-51713000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-90588000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2049000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	115000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2643000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4762000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47021000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85711000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-47021000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.20
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.20
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43468000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43468000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26751000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26751000	shares
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	927000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2092000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	927000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2092000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46094000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-87803000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	310466000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	116969000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9859000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9666000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	451000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	927000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-47021000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	401324000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	165657000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9739000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2092000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	447416000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-47021000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-85711000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	73000	usd
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	48000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2255000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3530000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9666000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9739000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1204000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1227000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14103000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7186000	usd
CY2023Q1	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	5621000	usd
CY2022Q1	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	4710000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7072000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6228000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-11276000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	280000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3218000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2860000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6791000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	3744000	usd
CY2022Q1	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	3487000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49088000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73482000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6079000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3585000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	36093000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22450000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	86976000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	70784000	usd
CY2023Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2506000	usd
CY2022Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	2500000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44798000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	44749000	usd
CY2023Q1	tsvt	Proceeds From Issuance Of Private Placement Net Of Issuance Costs ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts	117058000	usd
CY2022Q1	tsvt	Proceeds From Issuance Of Private Placement Net Of Issuance Costs ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9876000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	170000000	usd
CY2023Q1	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	150000	usd
CY2022Q1	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	99000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	127084000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	170099000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	122794000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	141366000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72290000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130448000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195084000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271814000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193629000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	270893000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1455000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	921000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	195084000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271814000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2342000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2925000	usd
CY2023Q1	tsvt	Accrued Stock Issuance Costs In Connection With Private Placement AccruedStockIssuanceCostsInConnectionWithPrivatePlacement	0	usd
CY2022Q1	tsvt	Accrued Stock Issuance Costs In Connection With Private Placement AccruedStockIssuanceCostsInConnectionWithPrivatePlacement	4343000	usd
CY2023Q1	tsvt	Accrued Stock Issuance Costs In Connection With Public Offering AccruedStockIssuanceCostsInConnectionWithPublicOffering	106000	usd
CY2022Q1	tsvt	Accrued Stock Issuance Costs In Connection With Public Offering AccruedStockIssuanceCostsInConnectionWithPublicOffering	0	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio, Inc. (the “Company” or “2seventy bio”) was incorporated in Delaware on April 26, 2021 and is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company’s approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, targeted cellular therapies for patients with cancer. The Company is advancing multiple preclinical and clinical programs in oncology and, together with Bristol-Myers Squibb (“BMS”), delivering the first U.S. Food and Drug Administration (“FDA”)-approved CAR T therapy in multiple myeloma, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abecma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (idecabtagene vicleucel, or ide-cel), to patients in the United States. Please refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative arrangements and strategic partnerships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further discussion of the collaboration with BMS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio Securities Corporation is a wholly-owned subsidiary of the Company which was incorporated in Massachusetts on December 13, 2021 and was granted securities corporation status in Massachusetts beginning in 2021. 2seventy bio Securities Corporation has no employees.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The separation from bluebird bio, Inc.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, bluebird bio, Inc. (“bluebird bio”) announced its plans to separate its oncology portfolio and programs from its severe genetic disease portfolio and programs, and spin off its oncology portfolio and programs into a separate, publicly traded company. In furtherance of this plan, on September 30, 2021, bluebird bio’s board of directors approved the distribution of all of the issued and outstanding shares of 2seventy bio common stock on the basis of one share of 2seventy bio common stock for every three shares of bluebird bio common stock issued and outstanding on October 19, 2021, the record date for the distribution. As a result of the distribution, which occurred on November 4, 2021, 2seventy bio became an independent, publicly traded company.</span></div><div style="margin-bottom:12pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company also entered into a separation agreement with bluebird bio, which is referred to in this quarterly report as the “Separation Agreement”, as well as various other agreements with bluebird bio, including a tax matters agreement, an employee matters agreement, an intellectual property license agreement, a transition services agreement under which 2seventy bio temporarily receives certain services from bluebird bio, and a second transition services agreement under which 2seventy bio temporarily provides certain services to bluebird bio. These agreements also govern certain of 2seventy bio’s relationships with bluebird bio after the separation. For additional information regarding the Separation Agreement and the other related agreements, refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-party transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the section captioned “Part III. Item 13. Certain Relationships and Related Transactions, and Director Independence,” included in our annual report on Form 10-K, which was filed with the SEC on March 16, 2023.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the three months ended March 31, 2023, the Company incurred a net loss of $47.0 million and used $49.1 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years. The Company's continued operations are dependent on its ability to raise additional funding and generate operating cash flows from the commercialization of its product candidates, if approved.</span></div>As of March 31, 2023, the Company had cash, cash equivalents, and marketable securities of $341.4 million. The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these financial statements. The Company intends to pursue additional cash resources through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. This includes the potential sale of shares of our common stock of up to $150.0 million in gross proceeds under the at-the-market (“ATM”) facility established in November 2022 with Cowen and Company, LLC. No sales of common stock have occurred under this ATM as of the date of this Quarterly Report on Form 10-Q. There can be no assurance that such financing will be available in sufficient amounts or on acceptable terms, if at all, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations.
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-47000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49100000	usd
CY2023Q1	tsvt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	341400000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7186000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73482000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	141366000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130448000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271814000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	921000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271814000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	74000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an </span></div>option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	148826000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1107000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	147733000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	198754000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2108000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	196652000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	45532000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	75450000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1033000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	120982000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1107000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	91385000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	278000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	88674000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1830000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	180059000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2108000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Amortized Cost RestrictedInvestmentsAvailableForSaleAmortizedCost	32806000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Accumulated Gross Unrealized Gain Before Tax RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Accumulated Gross Unrealized Loss Before Tax RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax	865000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Excluding Accrued Interest RestrictedInvestmentsAvailableForSaleExcludingAccruedInterest	31941000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Amortized Cost RestrictedInvestmentsAvailableForSaleAmortizedCost	32880000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Accumulated Gross Unrealized Gain Before Tax RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Accumulated Gross Unrealized Loss Before Tax RestrictedInvestmentsAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax	1112000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Excluding Accrued Interest RestrictedInvestmentsAvailableForSaleExcludingAccruedInterest	31768000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Continuous Unrealized Loss Position Less Than12 Months RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	4450000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Continuous Loss Position Less Than12 Months Accumulated Loss RestrictedInvestmentsAvailableForSaleContinuousLossPositionLessThan12MonthsAccumulatedLoss	27000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Continuous Unrealized Loss Position12 Months Or Longer RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	27491000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Continuous Loss Position12 Months Or Longer Accumulated Loss RestrictedInvestmentsAvailableForSaleContinuousLossPosition12MonthsOrLongerAccumulatedLoss	838000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Unrealized Loss Position RestrictedInvestmentsAvailableForSaleUnrealizedLossPosition	31941000	usd
CY2023Q1	tsvt	Restricted Investments Available For Sale Unrealized Loss Position Accumulated Loss RestrictedInvestmentsAvailableForSaleUnrealizedLossPositionAccumulatedLoss	865000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Continuous Unrealized Loss Position Less Than12 Months RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1942000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Continuous Loss Position Less Than12 Months Accumulated Loss RestrictedInvestmentsAvailableForSaleContinuousLossPositionLessThan12MonthsAccumulatedLoss	27000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Continuous Unrealized Loss Position12 Months Or Longer RestrictedInvestmentsAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	29826000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Continuous Loss Position12 Months Or Longer Accumulated Loss RestrictedInvestmentsAvailableForSaleContinuousLossPosition12MonthsOrLongerAccumulatedLoss	1085000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Unrealized Loss Position RestrictedInvestmentsAvailableForSaleUnrealizedLossPosition	31768000	usd
CY2022Q4	tsvt	Restricted Investments Available For Sale Unrealized Loss Position Accumulated Loss RestrictedInvestmentsAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1112000	usd
CY2023Q1	us-gaap	Interest Receivable InterestReceivable	700000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	300000	usd
CY2023Q1	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
CY2022Q1	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	109068000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	103573000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	49915000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47838000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	59153000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55735000	usd
CY2023Q1	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	19244000	usd
CY2022Q4	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	17962000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	11629000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13094000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4547000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14845000	usd
CY2023Q1	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	1858000	usd
CY2022Q4	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	1498000	usd
CY2023Q1	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	1692000	usd
CY2022Q4	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	1619000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	858000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	239000	usd
CY2023Q1	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	505000	usd
CY2022Q4	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	2005000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3235000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3416000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	43568000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	54678000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9666000	usd
CY2023Q1	tsvt	Number Of Performance Obligations NumberOfPerformanceObligations	2	performance_obligation
CY2018Q3	tsvt	Number Of Accounting Units NumberOfAccountingUnits	2	accounting_unit
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9739000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9666000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9739000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6249000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6249000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4470000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4470000	shares

Files In Submission

Name	View Source	Status
tsvt-20230331_cal.xml	Edgar Link	unprocessable
tsvt-20230331_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001860782-23-000076-index-headers.html	Edgar Link	pending
0001860782-23-000076-index.html	Edgar Link	pending
0001860782-23-000076.txt	Edgar Link	pending
0001860782-23-000076-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsvt-20230331.htm	Edgar Link	pending
tsvt-20230331.xsd	Edgar Link	pending
tsvt-pasteurlicenseagreeme.htm	Edgar Link	pending
tsvt-q1202310xqex311leschl.htm	Edgar Link	pending
tsvt-q1202310xqex312baird11.htm	Edgar Link	pending
tsvt-q1202310xqexhibit32111.htm	Edgar Link	pending
tsvt-20230331_pre.xml	Edgar Link	unprocessable
tsvt-20230331_lab.xml	Edgar Link	unprocessable
tsvt-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSVT
2seventy bio, Inc. Stock $tsvt

2023 Q2 Form 10-Q Financial Statement

#000186078223000076 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT 2seventy bio, Inc. Stock $tsvt

2023 Q2 Form 10-Q Financial Statement

#000186078223000076 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT
2seventy bio, Inc. Stock $tsvt